Straticyte™ Abstract Selected for Presentation at the AHNS 10th International Conference on Head and Neck Cancer

MaRS Discovery District, Toronto, ON; March 31, 2021 – Proteocyte AI, a personalized medicine and diagnostics company located at MaRS Centre, Toronto, ON, announces today that an abstract and poster titled “Assessing Risk of Oral Cancer Progression Using an S100A7 Immunohistochemical Signature-based Assay” will be presented at the American Head and Neck Society’s (AHNS) 10th International Conference on Head and Neck Cancer “Survivorship through Quality & Innovation”.

Dr. Mark Darling, a professor in Pathology at Western University (London, ON) and the presenting author of the abstract says: “I’m very excited to present some preliminary data around our Straticyte observational study which began back in 2015. This ongoing study involves patients from the general community, and while preliminary, the data so far indicates that Straticyte is more accurate at identifying lesions at true low-risk from elevated-risk of progressing to cancer.”

The AHNS Conference this year will be held between July 22 – 25 at the Hyatt Regency in Chicago, Illinois. It is an international conference that has been the world’s pre-eminent meeting for head and neck cancer since its inception in 1984 and is attended by nearly 2000 surgeons, oncologists, scientists and allied health professionals from around the world.

About Proteocyte

Proteocyte AI is a personalized medicine and diagnostics company located in MaRS Center, Toronto, ON. Proteocyte’s products help tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Sign up, read up, stay informed!

Join our mailing list to stay up-to-date with the latest news and activities from Proteocyte.

Thank you for subscribing to our newsletter!